Jump to Main Content

Annual Meeting

2021 Call for Abstracts

The 63rd Annual Meeting of the American Society of Hematology (ASH) will be held Saturday, December 11, through Tuesday, December 14, 2021, in Atlanta, Georgia. The goal of the ASH annual meeting is to present the best new scientific research in all areas of hematology. The meeting is planned as an in-person event in Atlanta, Georgia, and a virtual meeting is also planned for those that are unable to travel to Atlanta.

All abstract submissions must be made electronically through ASH’s online abstract submission system.

Please note the following changes for 2021:

  • Pre-recorded presentations for both oral and poster presentations are required by November 17th.
  • Presentation length for oral presentation is no longer than 10 minutes with 5 minutes of Q&A.
  • Poster presentations are 3-5 minutes including a slide deck and graphic poster for in-person and virtual attendees. Traditional posters will be hung in the poster hall for those attending in-person, and the poster image will be provided on the virtual platform.
  • Failure to submit presentation by November 17th will result in removal of presenting privileges, to be noted by “Presentation Not Available” in meeting materials.

Eligibility

To submit an abstract, the following criteria must be met:

  • At least one of the authors must be an ASH member who has paid the current membership dues.
  • If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor.
  • Research and/or studies must fit into one of the ASH 2021 Abstract Review Categories.
  • The ASH Annual Meeting is an accredited educational activity. ASH abides by guidelines formulated by the Accreditation Council for Continuing Medical Education (ACCME) limiting the participation of persons with financial relationships with ineligible companies (formerly commercial interests):
    • Ineligible companies are those whose primary business is producing, marketing, re-selling, or distributing healthcare products used by or on patients. Examples of such companies can be found on the ACCME website.
    • Abstracts with a presenting author who is (a) an employee of publicly traded or privately-held ineligible companies, or (b) owner of a privately-held company, will not be considered for oral presentation.

Abstract preprint criteria

  • Abstracts describing work posted to a preprint server prior to submission to ASH will be considered, but preprint posting must be disclosed and a link to the preprint provided.
  • Authors must retain copyright to the abstract so that it may be transferred to the American Society of Hematology if the abstract is accepted, per ASH’s copyright policy.
  • Once the abstract is submitted to ASH, no further changes can be made to the preprint, including the abstract, nor may it be updated if it is accepted for presentation.
  • Upon abstract acceptance for presentation at the annual meeting, the contents and conclusions of the abstract are embargoed from publication.



Any of the following criteria will make an abstract ineligible for presentation at the ASH annual meeting:

  • Data from peer-reviewed content publicly available via major search engines (such as PubMed, Google Scholar, etc.,
  • Data are accepted for journal publication before the abstract submission closing date.
  • Data have been or are to be presented at a meeting of 1,000 or more participants before the 2021 ASH annual meeting.
  • Data are to be presented at an ASH Friday Satellite Symposium, scheduled for December 10, 2021.

Updated analyses will be considered only if the abstract is a significant extension of previously published work. The author must provide an explanation (see section below) to show how the abstract contains significant new information.

.

  • The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system.
  • The presenting author must be one of the co-authors listed on the submitted abstract.
  • The presenting author is responsible for the following:
    • Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
    • Obtaining copyright transfer consent from co-authors.
      • For previously published abstracts, see Copyright below.
    • Forwarding all correspondence to all co-authors, including ASH policies and guidelines relating to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education.

  • Each abstract author agrees and certifies that he or she:
    • has read all of the rules and agrees to be bound by them,
    • is responsible for submission of the abstract in accordance with the rules, and
    • waives any and all claims against ASH and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract Policies

  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data. See Trials in Progress subsection below for information on submitting a Trial in Progress.
  • All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
  • Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please use the Updated Analyses section of the abstract form to explain the significance of the new data. The reviewers will have this information available during their evaluation.
  • Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.
  • Authors assign copyright of the abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such case, ASH does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
  • Submitters must disclose if the abstract has been previously published. For such abstracts, copyright remains with the current holder. By submitting a previously published abstract, submitter attests that they have gained permission from the copyright holder for the abstract to be displayed in the meeting mobile app and online program. Previously published abstracts will not be published in Blood; they will only be displayed digitally in non-enduring meeting materials.
  • Abstracts submitted to ASH are embargoed from the time of submission. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting is concluded. (Note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.) Read the “Embargo Policy” section of the Call for Abstracts for more information.
  • No revisions can be made after the abstract submission deadline.
  • Abstracts generally may not be withdrawn once submitted. During online submission, you must indicate whether you prefer to have your abstract withdrawn if it is not accepted as an oral or poster presentation at the ASH annual meeting. Abstracts may not be withdrawn after September 15.
  • There is a $85 nonrefundable handling fee for submitting an abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the annual meeting; therefore, all authors planning to attend the ASH annual meeting must register for the meeting.

During submission, submitters must choose the formats in which they would be willing to present/publish their abstract. These choices must be made at the time of submission and cannot be changed after the review committee has reached its decision. The same presentation format questions apply for Trials in Progress.

  • Authors select whether they prefer oral or poster presentation. Abstracts noted with a preference for poster presentation will NOT be considered for oral presentation, regardless of score.
    • Abstracts with a presenter who is an employee of publicly traded and privately-held ineligible companies, or owner of privately-held companies (see Conflict-of-Interest Disclosure Policy below) are NOT eligible for oral presentation. Submitters interested in oral presentation should select as presenter a co-author without an employee/owner relationship as defined below prior to the abstract deadline (August 4). Replacement of conflicted presenters after August 4 will not change the eligibility of the abstract.
  • Because the abstract withdrawal deadline (September 15 is before the notification date, submitters are strongly encouraged to consider the Preferred Presentation Format questions during submission if the outcome of the abstract is a deciding factor.
  • Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission. (It is assumed that the presenting author will have adequate command of English to present and to respond to questions. If that is not the case, the authors should choose a poster as their preference.)
  • In the event that an abstract is not chosen for oral presentation, it can still be chosen for poster presentation. Authors who state a preference for oral presentation must decide whether they would accept poster presentation. Authors may either present a poster or request that the abstract be immediately withdrawn. (Please note that declining to have your abstract considered for poster presentation does not improve its chances of being accepted as an oral presentation. This option should be selected primarily by authors who would not be willing to present a poster.)
  • In the event the abstract is NOT selected for presentation, all submitting authors must decide whether they want their abstract to be published in the online-only issue of Blood (which is part of the permanent Blood archive), or whether the abstract should be withdrawn completely and not published either online or in print. Published abstracts that are not selected for presentation will automatically be withdrawn.
  • The presentation at the annual meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract, although updates on results may be added.

Abstracts describing innovative Trials in Progress (TiP) [i.e., trials that have not reached the primary endpoint] are now eligible for submission and consideration for the ASH annual meeting program. TiPs abstracts are expected to provide investigators with opportunities to discuss planned and ongoing clinical trials; enabling translational researchers, clinical and industry investigators, statisticians, and regulators to become informed about these clinical trials and to allow for early engagement and collaboration, as appropriate. In addition, this platform will help increase the visibility of ongoing clinical trials; and ultimately facilitate patient recruitment.

In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria:

  • Trial described must fit into one of the ASH 2021 Abstract Review Categories.
  • Clinical studies submitted as TiP abstracts must be in the study-design phase, active, or ongoing and have NOT reached endpoints for analysis. Note: All phases of clinical research interventional studies (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion as a TiP submission.
  • Background: TiP abstracts should contain the scientific rationale for the trial to be presented. This rationale should include information on preclinical studies as well as previously published clinical data that informed and helped guide the development of the current study.
  • Study Design and Methods: The study design should be innovative and should highlight cutting-edge methodology. It must include:
    • A clinical trial registry number (if available);
    • A description of study population;
    • Major inclusion and exclusion criteria,
    • Statistical methods;
    • Biomarker selection or companion diagnostics (if appropriate), and
    • Study treatment, endpoints
  • The abstract must not contain any endpoint data but may contain information on regulatory issues, experience with recruitment, current recruitment status, patient characteristics, changes in inclusion and/or exclusion criteria, unexpected toxicities, and information on participating centers. Note: A few examples of studies that may be considered innovative include abstracts that illustrate adaptive trial design or novel approaches to biomarker identification. However, it will be at the discretion of the reviewers to select abstracts they believe highlight the most innovative science.

Abstract Review and Selection Process

  • After the submission deadline, all completed and eligible abstracts will be made available to the ASH Abstract Reviewers for blinded review and scoring, and final decisions will be made by the Program Committee in late September 2021.
  • Abstracts will be evaluated and scored solely on their scientific merits. Note: Trials in Progress abstracts will be flagged, and reviewers will be provided additional guidance for reviewing them (e.g., novelty of the methodology, quality of the study design and merit).
  • Incomplete abstracts will not be reviewed.
  • The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
  • Abstracts will be peer reviewed according to the subject categories. Authors must indicate during online submission the appropriate review category (one only). Please use the list of abstract review categories, which provides detailed descriptions of each category, to assist you in selecting the correct abstract classification. These categories have been updated; please read through all of the categories and select the category most closely associated with your abstract. Requests to change a review category will not be accepted after the closing of submissions.
  • All abstracts submitted (including Trials in Progress abstracts) will be considered eligible for one presentation: either plenary, oral (simultaneous session), or poster.

Note: All oral and poster presentations whether you attend in person or virtually will need to be pre-recorded and submitted by November 17th. Failure to submit presentation by the deadline will result in removal of presenting privileges, to be noted by “Presentation Not Available” in meeting materials.

  • The Plenary Session features the top six abstracts. These are formal oral presentations, each followed by a brief discussion. An ASH member selected by the Program Committee will give a brief introduction to the abstract.
  • Oral (simultaneous) Sessions are formal 10-minute oral presentations followed by a 5-minute discussion.
  • Poster Sessions allow the viewing of a poster illustration of the abstract. Poster presenters are required to complete a 3-5 -minute PowerPoint presentation of their poster as well as providing a graphic image of their poster for both in-person and virtual attendees. In-person presenters are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for their poster presentations. The author’s attendance during poster presentation time will be monitored.

  • Notification regarding acceptance or rejection of abstracts will be sent to the presenting author in early-October 2021 by e-mail; consequently, an accurate e-mail address is critical. If your abstract is accepted, the e-mail will specify whether it is accepted as plenary, oral, or poster presentation or whether it has been selected to be published online only. If you have not received an e-mail notification by October 5, 2021, contact ASHabstracts@hematology.org. Rejection notifications will also be sent at that time.
  • To ensure that you are able to receive e-mail correspondence from ASH, please make sure that your e-mail software can receive mail from the confex.com and hematology.org domains. You should add ash@confex.com and ASHAbstracts@hematology.org to your address book. If after completing your submission you don't receive a confirmation e-mail from the abstract system, you must contact your system administrator and make sure that both the confex.com and hematology.org domains are added to your e-mail address whitelist.
  • The decision of the ASH Program Committee regarding acceptance and presentation of abstracts is final.
  • All notifications will come from sender ASHabstracts@hematology.org. Please add this address to your Safe Senders list so you do not miss critical emails.
  • Once an abstract is accepted, a written request to withdraw must be submitted no later than September 15, 2021, to ASHabstracts@hematology.org if the first author decides to withdraw the abstract for any reason. Abstracts will not be withdrawn after this deadline.
  • ASH reserves the right to withdraw abstracts that are in violation of the Society’s policies and guidelines, such as those that have been previously published or presented, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
  • If you indicated at submission that you wish to withdraw your abstract if it is not accepted for either oral or poster presentation, your abstract will be automatically withdrawn, and you will be notified; you do not need to request withdrawal.
  • After the September 15 withdrawal deadline, the presenting author of a poster should submit a request to ASHabstracts@hematology.org to cancel the presented abstract (if a co-author cannot be identified to replace the presenter). A poster cancellation means that a “cancelled” sign will be hung on your board on the presentation date, and the abstract will remain published in the Webprogram, mobile app, and Blood supplement.
  • All abstracts accepted for presentation (plenary, oral, or poster) at the ASH annual meeting are published in a special online-only issue of Blood, ASH's official journal, on the Blood Abstracts website.
  • Previously published abstracts will not be published in Blood; they will only be displayed digitally in non-enduring meeting materials (e.g., mobile app and online program).
  • Abstracts not selected for presentation will be also be published online-only on the Blood Abstracts website. If an author does not want the abstract published if it is not accepted for presentation, he/she must indicate that during submission.
  • ASH reserves the right not to publish abstracts that do not fit into any of the review categories, abstracts that inappropriately promote commercial interests in the biomedical industry, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the Program Committee.

Recognizing that the results of some top-quality research may not be available by the general abstract submission deadline, the ASH Program Committee offers an option for late-breaking abstracts.

  • The late-breaking abstracts submission site will open October 19 and will close October 28, 2021.
  • During submission, authors of late-breaking abstracts will be asked to explain why their abstract was not ready by the regular deadline (August 4) and deserves to be considered as late-breaking. This information will be available to reviewers.
  • There is a $125 nonrefundable handling fee for submitting a late-breaking abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the annual meeting; therefore, all authors planning to attend the ASH annual meeting must register for the meeting.
  • Late-breaking abstracts will undergo regular peer-review evaluation.
  • Only six abstracts will be accepted and will be presented in the Late-Breaking Abstracts session on Tuesday, December 14.
  • The accepted abstracts will be published online-only at http://bloodjournal.hematologylibrary.org/site/misc/ASH_Meeting_Abstracts_Info.xhtml. Late-breaking abstracts not accepted for presentation will not be published in any form.

1. Conflict-of-Interest Disclosure Policy

  • ASH is committed to ensuring the integrity of its scientific, educational, and research programs. The ASH Conflict-of-Interest Policy requires disclosure of any financial or other interest in the biomedical industry that might be construed as resulting in an actual, potential, or apparent conflict, regardless of the relationship’s pertinence to the abstract, or abstracts if the author is associated with more than one abstract submitted to ASH.
  • As a continuing medical education (CME) provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), ASH must ensure balance, independence, objectivity, and scientific rigor in all presentations at the ASH annual meeting.
  • ASH abides by rules formulated by the ACCME that require that you disclose any financial relationship you or your spouse/partner have had within the past 24 months with an ineligible company (formerly commercial interest) as defined by the ACCME:
    • Ineligible companies are those whose primary business is producing, marketing, re-selling, or distributing healthcare products used by or on patients. Examples of such companies can be found on the ACCME website.
  • For this purpose, “financial relationships” are those in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committee or review panels, board memberships, and other activities from which remuneration is received, or expected. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds.
  • Further, employees of publicly traded and privately-held ineligible companies, and owners of privately-held companies, may not serve as presenting authors in an oral presentation.
    • Owners are defined as individuals who have an ownership interest in a company, except for stockholders of publicly traded companies, or holders of shares through a pension or mutual fund.
  • By completing this section of the online abstract submission, you agree that you have read the ASH Conflict-of-Interest Policy and that you understand and support its intent.
  • This policy is not intended to prevent a presentation; it is merely intended to openly identify potential conflicts so that audience members may form their own judgments about the presentation with a full disclosure of the facts.
  • Appropriate disclosure will be stated in the special online-only abstract issue of Blood. Abstracts will not be considered for the program without completion of disclosure information for all of the authors.

Author Responsibility Regarding Financial Relationship Disclosure

  • The presenting author is responsible for obtaining financial disclosure information from all co-authors.
  • All authors and co-authors are required to provide any information concerning personal or professional circumstances and financial relationships with ineligible companies that might reasonably be expected to affect the author’s view on the presentation.
  • This includes relationships with pharmaceutical companies, biomedical device manufacturers, biomedical startups that have begun a governmental regulatory approval process, or other companies whose products or services are related to the subject matter of the presentation topic. If no financial relationships with ineligible companies exist, this must be stated as well.

When to Disclose

Please disclose any relationships with ineligible companies regardless of the relationship’s pertinence to the content of the abstract, or abstracts if the author is associated with more than one abstract submitted to ASH. Disclosure includes relationships held by you or any individual with whom you directly share income.

What to Disclose

You must disclose the relationship type and the name of the ineligible company for each of the following areas in which you maintain a relationship. Exact dollar amounts are not necessary. You will have the option to (a) note that there are no financial relationships to disclose or to (b) provide relationship information. Disclosed information may include the following areas:

  • Employment (current or ended) [NOTE: abstract presenters with this conflict are ineligible for oral presentation]
  • Consultancy
  • Equity holder in publicly traded company
  • Equity holder in privately-held company (including stock options, but excluding indirect investments through mutual funds and the like) in a publicly traded company [NOTE: abstract presenters with this conflict are ineligible for oral presentation]
  • Research funding (including grants received by your institution)
  • Honoraria directly received from an entity
  • Patents and royalties
  • Paid expert testimony
  • Membership on an entity’s board of directors, speaker’s bureau, or its advisory committees
  • Any other financial relationship with an ineligible company

Off-Label Use

You will be required to note whether your presentation will include discussion of off-label use of products. If so, please use the Off-Label Disclosure section of the abstract form to identify the product(s) and off-label use(s).

Other Areas

During the disclosure submission process, you will also be required to indicate your compliance with the following statements, which include measures to ensure clinical content validity:

  • Any recommendations for patient care must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options.
  • All scientific research referred to, reported, or used in this educational activity in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation.
  • If I discuss new and evolving topics for which there is a lower (or absent) evidence base I will clearly identify it as such within the education and individual presentations.
  • The presentation of the information with which I am involved will avoid advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning.
  • The presentation of the information with which I am involved will exclude any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
  • The content I am responsible for will only use generic names of products, or if trade names appear, is the use of those trade names will be justified (e.g., product is known more widely for the trade name or the product does not have a generic name).
  • The content I am responsible for will be free of logos or other corporate identifiers of healthcare industry companies, specifically those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
  • I will remove all patient identifiers (name, birth date, address, phone number, medical record number, account number, social security number, etc.) from my presentation materials. I will not use identifiable photographs of patients unless I have obtained written permission from the patient.
  • If I have been trained or utilized by an ineligible company (commercial interest) or its agent as a speaker (e.g. speakers’ bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity or publication.
  • I agree not to accept honoraria or reimbursement, including travel support, from ineligible companies for my role as a chair/moderator/presenter in the accredited portions of this activity.

2. Embargo Policy

  • Abstracts submitted to the ASH annual meeting are embargoed from the time of submission.
  • For the research to be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented about the research at the annual meeting, may not be made public before the abstract has been published/presented at the ASH annual meeting.
  • Prior to the embargo being lifted, the first author, co-authors, and sponsor of the abstract must not:
    • Publish the information or provide it to others who may make it publicly available.
    • Release the research/study to news media, or
    • Use the information for trading in the securities of any issuer or provide it to others who may use it for securities-trading purposes.
  • An exception may be granted in cases in which the Securities and Exchange Commission (SEC) requires a press release to comply with security laws. ASH will consider such requests on an ad hoc basis. More information on requesting such an exception can be found on the ASH website.
  • Authors must notify ASH if, after the submission deadline, the data are accepted for journal publication and will be published online or in print before the ASH annual meeting. Publication before the meeting may result in the abstract being removed from the meeting.
  • If the Embargo Policy is violated, the abstract may be withdrawn by ASH from presentation at the annual meeting and from publication.
  • More detailed information about the Society’s Embargo Policy is located on the ASH website. Please contact ASH Communications Specialist Leah Enser at lenser@hematology.org or 202-552-4927 with any questions.

Submitting an Abstract

The abstract submission site is open June 1–August 3, 2021.

All abstracts must be submitted by August 3, 2021, at 11:59 p.m., Pacific Daylight Time. Submissions that are incomplete by the deadline will be rejected.

  • Abstracts must be submitted online through the official online abstract submission system. E-mails and word processing files not submitted through the site will not be accepted.
  • There is a $85 non-refundable handling fee for submitting an abstract. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the annual meeting; therefore, all authors planning to attend the ASH annual meeting must register [link] for the meeting.
  • Electronic submission works optimally with Microsoft Internet Explorer 7+, Mozilla Firefox 3.0+, and Safari or MAC OS 10.4+. Netscape Navigator 7.7+ is supported, but its use is discouraged, since not all features are available. The online abstract submission system will provide links so that you can download free browser software.
  • If this is the first time that you are submitting an abstract for the ASH annual meeting, please be sure to check the box that indicates this during submission.
  • Once you have submitted the title page information, a draft of your abstract will be saved, and you will be able to return to edit and update it at any time until August 3, 2021, at 11:59 p.m., PDT. You will receive an e-mail providing a link to your submission.
  • Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the “Submission Information” and “Disclosure” sections of the online abstract submission program.
  • Any technical questions regarding navigation of the submission site itself should be directed to ash@confex.com.

Contact Information

  • Your name, degree, institutional affiliation, address, phone number, and e-mail address must be provided. As the corresponding author, you will receive all future correspondence from ASH.
  • The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.
  • If none of the abstract authors is an ASH member, the program will ask you to provide the name of the ASH member who is sponsoring the abstract.

Co-Authors

  • Names of co-authors and their institutional affiliations must be provided. Please proof your co-authors’ names carefully.
  • The program will automatically place an asterisk (*) after the name of each non-member author. Changes will not be made to the spelling of authors’ names, nor the order of co-authors, after the submission deadline; please proof your co-authors’ names and order carefully.

Abstract Title

  • The abstract title should be brief and clearly indicate the nature of the abstract.
  • The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive.
  • Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
  • Do not put a period at the end of the title.
  • For example: Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies

Use of Product Names

  • Non-proprietary (generic/scientific) names should be used and should be lowercase.
  • If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ASH reserves the right to replace proprietary names with generic names to adhere to this policy.

Abbreviations

  • Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Abstract Body, Tables, and Figures

  • Abstracts submitted for the ASH annual meeting are published in a special online-only November 2021 issue of Blood, the Journal of the American Society of Hematology. Abstracts will be typeset from the text submitted by the author without copyediting changes. IT IS THE RESPONSIBILITY OF THE AUTHOR TO PROOFREAD THE ABSTRACT CAREFULLY. This includes the author list.
  • The entire body of the abstract, excluding tables, must not exceed 3,800 characters. Spaces are not included in this number. Title, authors’ names, affiliations, figures, and tables are not included in the character count.
  • The body of the abstract is to be pasted into the submission form. Tables and figures may be uploaded via photo file type.
  • The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
  • Do not use bold type or underline formatting. Italic type is acceptable.
  • Text may be in multiple paragraphs.
  • Special Greek and mathematical symbols are available in a character map within the submission system. Pay careful attention to superscripts, type case font sizes, and special characters when copy/pasting abstract text.
  • Use numerals to indicate numbers, except when beginning sentences.
  • All tables and figures that you wish to include must be uploaded as a single image file. Do not paste a table directly into the text of the abstract, but rather include it as an image in the appropriate place and use the upload method to submit your abstract. To convert a table to an image, we recommend taking a screenshot of the table. If using a PC, use the Snipping Tool or the Print Screen button. If using a Mac, press Command-Shift-4. An image can also be created by exporting your table in MS WORD to PDF format and then convert the file to an image.
  • Any references should be noted as citations within the text and not as footnotes at the end of the abstract.

Selection of Abstract Review Category

  • Please refer to the list of this year’s abstract review categories, which provides detailed descriptions of each category, to assist you in selecting the correct abstract classification. Note that categories are frequently restructured; please read through each category before making your selection.
  • Be sure to select from the review category that best describes your abstract. Note that the abstract will be reviewed in the category you selected; there is no re-classification once submission has closed.

ASH supports several types of awards for high-scoring abstracts submitted by hematologists-in-training.

How to be considered for an Abstract Achievement Award:

  • All hematologists-in-training, who are both first-or-last author and presenter of the abstract, are eligible for consideration for an Abstract Achievement Award. Submitters must first identify as a hematologist–in-training, select the appropriate training category (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow), and opt into award consideration in the online abstract submission system.
  • As a hematologist-in-training, you are required to submit a letter from the senior investigator overseeing your research confirming your status as a hematologist-in-training.
  • Your letter must be typed on your institution’s letterhead, signed by the senior investigator, saved in PDF format, and uploaded to the online abstract submission system.
  • Please include the following items in your letter:
    • Author name (this is the hematologist-in-training who is the presenting/contact author)
    • Confirmation of your specific training category and status as a hematologist-in-training

All hematologist-in-training authors must upload the required letter into the program in order to complete the abstract submission. The deadline for receipt of the hematologist-in-training letter is therefore, August 3, 2021. There will be no exceptions.

Outstanding Abstract Achievement Awards
  • ASH Outstanding Abstract Achievement Awards are provided to abstract presenters who are the first-or-last authors of the highest scoring abstracts in their career level. There is one award for each of the following categories: undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow (MD or PhD).
  • Outstanding Abstract Achievement Award winners receive a $500 honorarium plus annual meeting travel reimbursement (coach airfare and two nights' hotel accommodations).
  • Abstract Achievement Award recipients will be notified if they will receive an award by late October 2021.
  • Winners must attend the meeting and present their abstract to receive their award.
Abstract Achievement Awards
  • Undergraduate students, medical students, graduate students, resident physicians, and post-doctoral (MD or PhD) fellows who are both first-or-last author and presenter of the abstract are eligible for an ASH Abstract Achievement Award.
  • ASH Abstract Achievement Awards are merit-based awards in the amount of $500 offered to trainees with high-scoring annual meeting abstracts.
  • Abstract Achievement Award recipients will be notified by email if they will receive an award by late October. The list of award recipients will also be posted on the ASH website by November.
  • Winners must attend the meeting and present their abstract to receive their award.
ASH Giuseppe Bigi Memorial Award
  • This annual award is given to an Italian trainee (undergraduate, medical, or graduate student, resident physician, or post-doctoral fellow) based at an Italian institution who is both the first-or-last author and presenter of the highest-scoring abstract submitted to the ASH annual meeting in the field of hematopoiesis and stem cells.
  • The recipient receives a $4,000 honorarium and $1,000 travel allowance to attend the ASH annual meeting.
  • This annual award is made possible by a grant from the Giuseppe Bigi Association, named for the late Giuseppe Bigi, MD, a well-known Italian scientist. Dr. Bigi served as associate professor of Clinical Immunology at the University of Milan from 1985 until his death in 2002 and was one of the first researchers to predict the presence of stem cells in the peripheral blood.
ASH-HSANZ Abstract Achievement Award
  • This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are both the first-or-last author and presenter of the highest-scoring abstract.
  • Each awardee shall receive a $2,000 grant and complimentary registration to the current year’s ASH annual meeting.
  • Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.
ASH-JSH Abstract Achievement Award
  • This annual award in partnership with the Japanese Society of Hematology (JSH) shall be granted to up to three trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are both the first-or-last author and presenter of the highest-scoring abstract.
  • Each awardee shall receive a $2,000 grant and complimentary registration to the current year’s ASH annual meeting.
  • Recipients of this award must be members of JSH and reside in Japan.
ASH-SIE Abstract Achievement Award
  • This annual award in partnership with the Society Italiana di Ematologia (SIE) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are both the first-or-last author and presenter of the highest-scoring abstract.
  • Each awardee shall receive a $2,000 grant and complimentary registration to the current year’s ASH annual meeting.
  • Recipients of this award must be a member of SIE and reside in Italy.
ASH-IPIG Abstract Achievement Award for Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) shall be granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.
  • The recipients of the award shall each receive a $2,000 grant.
  • This is award is made possible by the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group. IPIG is dedicated to enhancing and expanding professional knowledge about paroxysmal nocturnal hemoglobinuria (PNH) and related disorders in order to improve patient treatment and care.
Mary Rodes Gibson Memorial Award in Hemostasis & Thrombosis
  • This annual award is given to a trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral [MD or PhD] fellow) who is both the first-or-last author and presenter of the highest scoring abstract submitted in the field of hemostasis and thrombosis.
  • The recipient receives a $5,000 grant and a $1,000 allowance for travel and expenses to the ASH annual meeting.
  • This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson, who suffered from severe, type 3 von Willebrand disease.
  • The winner of this award will also present their abstract at the invited speaker session of the Special Symposium on the Basic Science of Hemostasis and Thrombosis.
Minority Graduate Student Abstract Achievement Award (separate application required!)
  • This award recognizes minority PhD students at U.S. or Canadian institutions whose abstracts have been accepted for oral or poster presentation at the ASH annual meeting.
  • Minority Graduate Student Abstract Achievement Award recipients receive a $1,500 grant to attend the ASH annual meeting.
  • Minority Graduate Student Abstract Achievement Award applicants will be notified as to whether or not they received an award by late October. Please contact ASH Headquarters at awards@hematology.org if you have not heard about the status of your award by November 1.
  • Winners must attend the meeting and present their abstract to receive their award.

Additional requirements to apply for the Minority Graduate Student Abstract Achievement Award:

  • To apply, applicants must first submit an abstract as a hematologist-in-training to the ASH annual meeting through the online abstract submission system by August 3, 2021.
  • Applicants must also submit a program application to awards@hematology.org by 11:59 PM PST on August 3, 2021.
  • For complete eligibility requirements and to download the program application, please visit www.hematology.org/Awards.

Completion of all required disclosure information in the online abstract submission system serves as an agreement and is accepted in lieu of a faxed signature. It certifies the ASH abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:

  1. All authors approve of submitting this work for presentation and publication;
  2. The author(s) transfer(s) all copyright ownership of the named abstract to the American Society of Hematology (except when one or more authors are U.S. Government employees); OR the submitter has gained permission from the copyright holder of the previously published abstract for the abstract to be displayed in the ASH meeting mobile app and online program.
  3. All authors have read the ASH Conflict-of-Interest Policy and have acted in accordance with that policy;
  4. The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session;
  5. The presenting author will be available to present the abstract if selected for the program. The author(s) will immediately notify ASH if the presenting author must be changed;
  6. The data in the abstract are not publicly available via major search engines; have not been accepted for publication before the abstract submission closing date; nor will they be materially presented at a meeting of 1,000 or more participants before the ASH annual meeting (note the exception for abstracts submitted to other ASH meetings in the Eligibility section above.); and are not to be presented at an ASH Friday Satellite Symposium; and
  7. The author(s) are aware that the withdrawal deadline for ASH Annual Meeting abstracts is September 15, 2021, and understand that abstracts cannot be withdrawn after September 15.

A sample abstract is provided for your reference below. Note that the title, authors, and institutions are entered in separate fields in the submission form, not in the abstract body, as they are not included in the character count.

The LRF/ZBTB7A Transcription Factor Is a BCL11A-Independent Repressor of Fetal Hemoglobin
Takeshi Masuda, PhD1, Xin Wang, PhD2, Manami Maeda, M.D., PhD1, Matthew C. Canver, B.S.3, Falak Sher, PhD3, Alister P.W. Funnell, PhD4, Chris Fisher, PhD5, Maria Suciu5, Gabriella E. Martyn4, Laura J. Norton4, Ruijia Zhu1, Ryo Kurita, PhD6, Yukio Nakamura, MD, PhD6, Jian Xu, PhD7, Douglas R. Higgs, FRS5, Merlin Crossley, DPhil4, Daniel E. Bauer, MD, PhD3, Stuart H. Orkin, M.D.8, Peter V. Kharchenko, PhD2 and Takahiro Maeda, MD, PhD1
1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2Department of Biomedical Informatics, Harvard Medical School, Boston, MA
3Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia
5MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom
6Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Japan
7Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX
8Department of Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Induction of fetal-type hemoglobin (HbF: α2γ2) is a promising means to treat hemoglobinopathies; however, precisely how HbF expression is silenced in adult erythroid cells is not fully understood. Such knowledge is essential to develop mechanism-based, targeted approaches to reactivate HbF production. Here, we show that Leukemia/lymphoma Related Factor (LRF), encoded by the ZBTB7A gene, is a novel and potent repressor of HbF production.

To assess the effects of LRF loss on the mouse erythroid transcriptome, we performed RNA-Seq analysis using splenic erythroblasts from control and LRF conditional knockout (Zbtb7aF/F Mx1-Cre+) mice. LRF-deficient adult erythroblasts showed significant induction of Hbb-bh1, but not Hbb-y. The results were validated at the protein levels via isoelectric focusing of peripheral blood (PB) hemolysates and MALDI-TOFMS analysis. LRF loss also reactivated human fetal globin expression in vivo in LRF conditional KO mice harboring the human β-globin gene cluster as a yeast artificial chromosome transgene (β-YAC).

To determine whether LRF loss could induce HbF in human erythroid cells, we employed human CD34+ hematopoietic stem and progenitor (HSPC)-derived primary erythroblasts and determined γ-globin expression levels upon shRNA-mediated LRF knockdown (KD). HbF levels in LRF KD cells (49-70%) were much greater than those seen in parental or scrambled-shRNA transduced cells. We next employed a novel human immortalized erythroid line (HUDEP-2). This line possesses an advantage over lines currently used for globin switching studies because it expresses predominantly adult hemoglobin (HbA: α2β2), with very low background HbF expression. Using CRISPR/cas9 gene modification, we knocked out ZBTB7A in HUDEP-2 cells and performed RNA-Seq analysis. As expected, γ-globin (HBG1 and HBG2) transcripts, but not those of embryonic ε-globin (HBE1), were markedly induced in ZBTB7A KO (ZBTB7AΔ/Δ) HUDEP-2 cells. ZBTB7AΔ/Δ cells exhibited HbF levels greater than 60%, while that of parental cells was less than 3%. Notably, the HbF reactivation occurred without changes in levels of transcripts encoding known HbF repressors, including BCL11A, the principal known switching factor.

We next performed chromatin-immunoprecipitation and sequencing (ChIP-Seq) with an anti-LRF antibody using HSPC-derived proerythroblasts and HUDEP-2 cells. The most enriched motif identified in either was concordant with that previously identified in vitro using CAST analysis (Maeda et. al. Nature 2005), confirming antibody specificity. Supporting a direct role of LRF at the β-globin cluster, we observed several significant enrichment of LRF-ChIP binding signals at adult (HBB), fetal (HBG1) globin loci and the upstream hypersensitivity (HS) sites within the locus control region (LCR). ATAC-Seq (for assay for transposase-accessible chromatin with high-throughput sequencing) analysis revealed strong chromatin accessibility at the γ-globin locus in ZBTB7AΔ/Δ cells. Strikingly, differential enrichment of ATAC-signals in ZBTB7AΔ/Δ cells was evident only at the γ-locus. Thus, while LRF binds to the HBB locus and HS sites as well as to the HBG1 locus, LRF depletion specifically opens chromatin at the γ-globin locus.

Finally, to determine whether LRF and BCL11A suppress γ-globin expression via distinct mechanisms, we established LRF/BCL11A double knockout HUDEP-2 cells. Strikingly, HUDEP-2 lines lacking both LRF and BCL11A exhibited almost a complete switch in expression from adult- to fetal-type globin, suggesting that these two factors cumulatively represent the near entirety of γ-globin repressive activity in adult erythroid cells. Our findings reveal a novel molecular mechanism regulating γ-globin silencing and may open a new window for therapeutic targeting in the treatment of hemoglobinopathies.

Contact Information

Send related correspondence and questions regarding abstract submissions or notifications to: ASHabstracts@hematology.org.

Any technical questions regarding navigation of the submission site itself should be directed to ash@confex.com.

ASH Annual Meeting Registration and Housing

  • Please note that submitting an abstract does not register you for the ASH annual meeting.
  • To register, you must complete and return an Attendee Registration Form, or register online through the ASH website.
  • For ASH members, Early-Bird Registration will be available July 21, 2021. During this time, ASH members can access the online meeting registration and hotel reservation program before it is open to the general public.
  • Please note that Early-Bird Registration is available online only, and you must register for the annual meeting before making your hotel reservations.
  • The Preliminary Program, which includes registration, hotel reservation, and program information, will be available online in July 2021.
  • Non-members will be able to find all relevant annual meeting information on the ASH website and can access the online registration and hotel reservation program beginning August 11, 2021.
  • To register as a non-member in training and receive the discounted advance registration rate, you must register and submit your trainee verification via the online registration site by December 10, 2021. Trainee verification will not be accepted at on-site registration in Atlanta and the discounted rate will not apply.

Related Content